Carnot institutes & companies

<h3> IFPEN Transports Energy Carnot Institute : new alliance with the SME EASYLI about an R&D agreement in the field of energy storage.</h3> <p> <strong>IFP Energies nouvelles (IFPEN) and the SME EASYLI have just signed an R&D agreement to jointly develop and market innovative solutions for batteries and electric energy storage systems.</strong></p> <p> The aim of the EASYLI - IFPEN partnership is to design and develop competitive solutions to improve the performance, durability and safety of battery systems. It is underpinned by IFPEN's R&D expertise, covering electrical engineering, control/command, electrochemical and electronic modeling, and the physicochemistry of Lithium batteries. The development of new generations of electronics for active battery balancing and coupling is already well advanced.</p> <p> Given the complementary nature of their respective expertise, EASYLI and IFPEN see in this partnership an outstanding opportunity to bring to market innovative energy storage solutions for both stationary (residential, tertiary and industrial self-consumption, energy provision at remote locations) and mobile (light electric vehicles and special vehicles) applications.<br /><em><strong><a href="http://www.ifpenergiesnouvelles.com/News/Press-releases/New-alliance-in…; target="_blank">Read more</a></strong></em></p> <h3> Curie Cancer Carnot Institute and GamaMabs Pharma renew their research partnership to develop an antibody for gynecological cancers</h3> <p> <strong><a href="/en/carnot-institute/curie-cancer" target="_blank">Curie Cancer Carnot Institute </a>and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, announced the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.</strong></p> <p> An initial partnership agreement was concluded in 2013. The results of work on the 3C23K antibody were presented to the Ovarian Cancer Research Symposium in Seattle in September 2014. The partnership agreement has been renewed and extended in order to further examine the efficacy of this candidate drug for ovarian cancer.<br /> Models of mice were grafted with human tumor samples from the operating theaters at the Institut Curie. In particular, the partners are exploring the value of 3C23K in relapses; a major challenge in the treatment of this disease.<br /> Ovarian cancer is responsible for over 50,000 deaths a year in Europe and the US.<br /><strong><em><a href="/sites/default/files/images/CP-2014_CurieCancer_GamaMabs_UK.pdf" target="_blank">Read more</a></em></strong></p> <h3> The Télécom & Société Numérique Carnot Institute accredits technology research platforms for companies</h3> <p> <strong>The <a href="/en/carnot-institute/telecom-societe-numerique" target="_blank">Télécom & Société Numérique Carnot Institute</a></strong> (which consists of the Télécom schools of Institut Mines-Télécom, Eurecom, Télécom Saint-Etienne, Télécom Physique Strasbourg, two Polytechnic laboratories and the Strate design school) <strong>recently awarded labels of excellence (TSN Carnot Platform) to 6 technology platforms which are accessible to companies and located across different regions in France (within the members of the TSN Carnot themselves).</strong><br /> Offering such accredited platforms entails the highest level of expertise and state of the art equipment in precise fields. They are open to public and private researchers for development of their research, exchanges of results, proof of concepts, tests, experiments and training.<br /><strong><em><a href="http://www.mines-telecom.fr/en/telecom-societe-numerique-carnot-institu…; target="_blank">Read more</a></em></strong></p>